Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK3 | P49761 | 18/20 | 0.69 |
| ▸ | DYRK1A | Q13627 | 18/20 | 0.69 |
| ▸ | CLK2 | P49760 | 17/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
| ▸ | WNT1 | P04628 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13655258 | 0.87 | CLK3 (0.72) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL13655271 | 0.86 | DYRK1A (0.69) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL18485128 | 0.82 | CLK3 (1.00) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL18446560 | 0.82 | CLK3 (0.82) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL13655287 | 0.82 | CHEK1 (0.68) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL18482640 | 0.80 | CLK3 (0.82) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL18441945 | 0.79 | DYRK1A (0.78) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL20455095 | 0.74 | DYRK1A (0.82) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL18487462 | 0.74 | DYRK1A (0.69) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL5635858 | 0.74 | CLK3 (0.69) | CLK3DYRK1ACLK2WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MAPT, PSEN2, PSEN1 | CLK3 1342/4885DYRK1A 1225/4885CLK2 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.